
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).
Revolutionizing cancer detection: AI-driven multi-omics enhances sensitivity for MRD and MCED assays. ππ¬









